The adage you are what you eat’ is more than folk wisdom. Evidence that the food you ingest has a major impact on your health grows by the day. It’s now clear the bacteria that colonise the skin and gut from birth on are key sensors for environmental triggers in chronic diseases of civilisation. Ever since research showed that restoring microbiome balance cures 90% of all Clostridium difficile infections, food manufacturers, pharma companies and independent teams have been tracking it in other indications – including multiple sclerosis.
https://european-biotechnology.com/wp-content/uploads/2024/04/EB_Winter_2017_miraculousmicrobiome.jpg12002000Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2018-03-08 15:00:002024-04-02 16:21:29Learning to listen to your gut
Evotec and Sanofi want to create an Evotec-led infectious disease open innovation R&D platform at Sanofi’s antiinfectives hub in Lyon. Talks are expected to close in H1/2018 with an option agreement.
Forendo Pharma, a drug development company developing novel oral treatments for endometriosis patients, today announces the appointment of David Colpman as a non-executive director to its Board of Directors.
https://european-biotechnology.com/wp-content/uploads/2024/04/jamiemacdonaldparexel.jpg343343h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2018-03-07 13:50:012018-03-07 13:50:01Parexel Appoints Jamie Macdonald as CEO
https://european-biotechnology.com/wp-content/uploads/2024/04/Pharmapack_2018.jpg450800Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2018-03-07 09:41:472024-04-02 16:21:30Experts forecast the industry’s biggest developments at Pharmapack Europe
Under an exclusive licence option agreement, Heidelberg Pharma will develop ATACs (alpha-amanitin antibody conjugates) for Magenta Therapeutics Inc. across several targeted conditioning programmes for bone marrow transplants.
Investments into new drugs to tackle antimicrobial resistance (AMR) are set to boost the participation of SMEs. At the 11th Berlin Conference on Life Sciences, two new financing initiatives, which focus on innovations developed by SMEs, were presented to 200+ AMR stakeholders.
https://european-biotechnology.com/wp-content/uploads/2024/04/Aleks_Engel_at_Berlin_Conference.jpg540960Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2018-03-05 17:39:552018-03-05 17:39:55Investors keen to put money into AMR SMEs
Swiss Santhera Pharmaceuticals EU-approved LHON treatment Raxone (idebenone) has failed to show clinical efficacy in another indication: After US and EU regulators rejected an extension of market approval in Duchenne muscular dystrophy last September, an NIH-sponsored trail now showed no difference to placebo treatment in patients with primary progressive multiple sclerosis (PPMS).
https://european-biotechnology.com/wp-content/uploads/2024/04/Radek_S__pi__s__ek.jpg190190h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2018-03-02 00:00:002018-03-02 00:00:00Radek píek to become new CEO of SOTIO
Learning to listen to your gut
BackgroundThe adage you are what you eat’ is more than folk wisdom. Evidence that the food you ingest has a major impact on your health grows by the day. It’s now clear the bacteria that colonise the skin and gut from birth on are key sensors for environmental triggers in chronic diseases of civilisation. Ever since research showed that restoring microbiome balance cures 90% of all Clostridium difficile infections, food manufacturers, pharma companies and independent teams have been tracking it in other indications – including multiple sclerosis.
Sanofi to outsource antiinfectives R&D to Evotec
Latest NewsEvotec and Sanofi want to create an Evotec-led infectious disease open innovation R&D platform at Sanofi’s antiinfectives hub in Lyon. Talks are expected to close in H1/2018 with an option agreement.
David Colpman joins Forendo Pharma’s Board of Directors
AppointmentsForendo Pharma, a drug development company developing novel oral treatments for endometriosis patients, today announces the appointment of David Colpman as a non-executive director to its Board of Directors.
Parexel Appoints Jamie Macdonald as CEO
AppointmentsCompany Co-founder Josef von Rickenbach to retire after 35 years of leadership; serve as Chairman of the Board.
Experts forecast the industry’s biggest developments at Pharmapack Europe
BackgroundPersonalised medicines, intelligent packaging and FDA deadlines seen as major trends for pharma packaging in 2018.
Heidelberg Pharma inks US$334m R&D contract with Magenta Therapeutics
Latest NewsUnder an exclusive licence option agreement, Heidelberg Pharma will develop ATACs (alpha-amanitin antibody conjugates) for Magenta Therapeutics Inc. across several targeted conditioning programmes for bone marrow transplants.
Brief Overview of The Trianni Mouse Platform
Sponsored PublicationsTRIANNI’s antibody discovery platform, The Trianni Mouse, represents best-in-class technology for efficient generation of fully-human monoclonal antibodies.
Investors keen to put money into AMR SMEs
Latest NewsInvestments into new drugs to tackle antimicrobial resistance (AMR) are set to boost the participation of SMEs. At the 11th Berlin Conference on Life Sciences, two new financing initiatives, which focus on innovations developed by SMEs, were presented to 200+ AMR stakeholders.
Santhera’s idebenone not efficient in PPMS patients
Latest NewsSwiss Santhera Pharmaceuticals EU-approved LHON treatment Raxone (idebenone) has failed to show clinical efficacy in another indication: After US and EU regulators rejected an extension of market approval in Duchenne muscular dystrophy last September, an NIH-sponsored trail now showed no difference to placebo treatment in patients with primary progressive multiple sclerosis (PPMS).
Radek píek to become new CEO of SOTIO
AppointmentsSOTIO, a biotechnology company belonging to the PPF Group, announces today the appointment of Professor Radek píek as Chief Executive Officer.